Detalles de la búsqueda
1.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Lancet
; 402(10412): 1541-1551, 2023 10 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738999
2.
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3â years of treatment in randomized phase III trials.
Br J Dermatol
; 190(4): 477-485, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37950894
3.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38451052
4.
Effects of Carbon Templates in Tetraethyl Orthosilicate-Derived Superhydrophobic Coatings.
Langmuir
; 39(15): 5495-5504, 2023 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018471
5.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115523
6.
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
J Allergy Clin Immunol
; 149(6): 2010-2020.e8, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34767869
7.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet
; 397(10273): 475-486, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549192
8.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet
; 397(10273): 487-498, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549193
9.
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
N Engl J Med
; 379(14): 1313-1321, 2018 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30205746
10.
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
J Am Acad Dermatol
; 84(2): 432-470, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32738429
11.
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
Dermatology
; 237(1): 46-55, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-31962340
12.
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 82(4): 936-945, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31809827
13.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
J Am Acad Dermatol
; 82(1): 161-201, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31703821
14.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
J Am Acad Dermatol
; 82(6): 1445-1486, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32119894
15.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res
; 29(2): 369-380, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655974
16.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet
; 392(10148): 650-661, 2018 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-30097359
17.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 375(4): 345-56, 2016 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27299809
18.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
J Am Acad Dermatol
; 81(3): 775-804, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31351884
19.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
J Am Acad Dermatol
; 80(4): 1073-1113, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772097
20.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
J Am Acad Dermatol
; 80(4): 1029-1072, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772098